AYTU BIOPHARMA, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AYTU BIOPHARMA, INC. on January 4, 2022. The report discloses the appointment of a new Chief Financial Officer and the associated unregistered sale of equity securities as an inducement award.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation and equity issuance.
Material Changes
The primary material change is the appointment of Mark Oki as Chief Financial Officer, effective January 17, 2022. Concurrently, the Company agreed to issue 100,000 shares of common stock to Mr. Oki as an inducement award under NASDAQ Listing Rule 5635(c)(4).
Management Commentary and Compensation Details
Mr. Oki's employment agreement includes the following compensatory arrangements:
- Base Salary: $415,000 annually.
- Target Bonus: 40% of base salary contingent on performance milestones.
- Signing Bonus: $50,000.
- Equity Grant: 100,000 shares of restricted stock subject to vesting provisions.
- Severance: Upon termination without cause or for good reason, Mr. Oki is entitled to one year of base salary plus earned incentives, 12 months of COBRA coverage, and accelerated vesting of restricted stock.
- Change in Control: Triggers a payment equal to one times base salary plus target bonus, 12 months of COBRA, and accelerated vesting of all stock options or awards.
The 100,000 shares are exempt from registration under Section 4(a)(2) of the Securities Act and Regulation D. The Company intends to file a Form S-8 to register these shares.
Investor Verification Checklist
- Verify the effective date of the CFO appointment (January 17, 2022).
- Confirm the vesting schedule and specific terms of the 100,000 restricted stock shares in the upcoming Form 10-Q.
- Review the full text of the CFO Employment Agreement and Restricted Stock Award Agreement once filed.
- Monitor the filing of the Form S-8 registration statement for the inducement award shares.